Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?

Adrian Post*, Dion Groothof, Michele F. Eisenga, Stephan J. L. Bakker

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Downloads (Pure)

Abstract

Inhibitors of sodium-glucose cotransporter 2 (SGLT2) have emerged as practice-changing treatments for patients with type 2 diabetes, reducing both the risk of cardiovascular events and kidney events. However, regarding the latter, caution is warranted, as these kidney endpoints are defined using glomerular filtration rate estimations based on creatinine, the non-enzymatic product of creatine residing in muscles. Creatinine-based estimations of the glomerular filtration rate are only valid if the treatment has no effect on changes in muscle mass over time. Yet, circumstantial evidence suggests that treatment with SGLT2 inhibitors does result in a loss of muscle mass, rendering serum creatinine-based kidney endpoints invalid. Currently, it cannot be excluded that the described renoprotective effect of SGLT2 inhibitors is in part or in whole the consequence of a loss of muscle mass. Post-hoc analyses of existing trials or new trials based on kidney function markers independent of muscle mass can provide more definitive answers on the proposed renoprotective effects of SGLT2 inhibitors.

Original languageEnglish
Article number1603
Number of pages11
JournalJournal of Clinical Medicine
Volume9
Issue number5
DOIs
Publication statusPublished - May-2020

Keywords

  • SGLT2 inhibitors
  • muscle mass
  • eGFR
  • renoprotection
  • TYPE-2 DIABETES-MELLITUS
  • FAT MASS
  • JAPANESE PATIENTS
  • CARDIOVASCULAR OUTCOMES
  • DIALYSIS INITIATION
  • VISCERAL FAT
  • BODY-WEIGHT
  • IPRAGLIFLOZIN
  • DAPAGLIFLOZIN
  • MORTALITY

Cite this